Achievement of deep molecular response and treatment-free remission with asciminib treatment in CML
We evaluated the possibility of treatment-free remission (TFR) and durability of deep molecular response (DMR) with asciminib treatment by monitoring major BCR::ABL mRNA on the International Scale (BCR::ABL-IS) in 4 patients who needed to reduce or discontinue asciminib due to adverse event concerns...
Gespeichert in:
| Veröffentlicht in: | International journal of hematology 2024-10, Vol.120 (4), p.512-514 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 514 |
|---|---|
| container_issue | 4 |
| container_start_page | 512 |
| container_title | International journal of hematology |
| container_volume | 120 |
| creator | Yoshimaru, Ryo Minami, Yosuke |
| description | We evaluated the possibility of treatment-free remission (TFR) and durability of deep molecular response (DMR) with asciminib treatment by monitoring major BCR::ABL mRNA on the International Scale (BCR::ABL-IS) in 4 patients who needed to reduce or discontinue asciminib due to adverse event concerns, intolerance, or personal circumstances. IS increased in all 4 patients after discontinuation of asciminib, but 3 patients who resumed asciminib achieved DMR again. None of the patients achieved TFR with asciminib, but DMR could be achieved again by restarting asciminib after TFR failure. As this was a retrospective study in a small number of patients, no conclusions can be drawn regarding the possibility of TFR with asciminib. However, this study included patients with short treatment duration and DMR maintenance periods, so strict conditioning may be necessary. Safe dose reduction or TFR with asciminib may need to be considered in more cases. |
| doi_str_mv | 10.1007/s12185-024-03816-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3082311700</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3082311700</sourcerecordid><originalsourceid>FETCH-LOGICAL-c256t-d275abfca987e05613d6761e940f21e1934a6473fae6ae8cc31e526f6d02b353</originalsourceid><addsrcrecordid>eNp9kUtvFDEQhC1ElCwhf4ADssSFi0m3PX7MMVqFh7SIS-6W19NDHM1jsWcg_HscNhCJA6c-9NfVpSrGXiG8QwB7WVCi0wJkI0A5NOL-GdugM1ooa5vnbAOt1EJbhDP2opQ7ALTQ2FN2plqQyrhmw-JVvE30nUaaFj73vCM68HEeKK5DyDxTOcxTIR6mji-ZwvIAij4T1d2YSknzxH-k5ZaHEtOYprR_4nia-Pbz7iU76cNQ6OJxnrOb99c3249i9-XDp-3VTkSpzSI6aXXY9zG0zhJog6oz1iC1DfQSCVvVBNNY1QcygVyMCklL05sO5F5pdc7eHmUPef62Ull89RdpGMJE81q8AicV1gigom_-Qe_mNU_VnFcIVqFzLVZKHqmY51Iy9f6Q0xjyT4_gHxrwxwZ8bcD_bsDf16PXj9LrfqTu78mfyCugjkCpq-kr5aff_5H9BdejkdE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3107318891</pqid></control><display><type>article</type><title>Achievement of deep molecular response and treatment-free remission with asciminib treatment in CML</title><source>SpringerLink Journals - AutoHoldings</source><creator>Yoshimaru, Ryo ; Minami, Yosuke</creator><creatorcontrib>Yoshimaru, Ryo ; Minami, Yosuke</creatorcontrib><description>We evaluated the possibility of treatment-free remission (TFR) and durability of deep molecular response (DMR) with asciminib treatment by monitoring major BCR::ABL mRNA on the International Scale (BCR::ABL-IS) in 4 patients who needed to reduce or discontinue asciminib due to adverse event concerns, intolerance, or personal circumstances. IS increased in all 4 patients after discontinuation of asciminib, but 3 patients who resumed asciminib achieved DMR again. None of the patients achieved TFR with asciminib, but DMR could be achieved again by restarting asciminib after TFR failure. As this was a retrospective study in a small number of patients, no conclusions can be drawn regarding the possibility of TFR with asciminib. However, this study included patients with short treatment duration and DMR maintenance periods, so strict conditioning may be necessary. Safe dose reduction or TFR with asciminib may need to be considered in more cases.</description><identifier>ISSN: 0925-5710</identifier><identifier>ISSN: 1865-3774</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-024-03816-x</identifier><identifier>PMID: 39023684</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>BCR-ABL protein ; Case Report ; Case reports ; Drug dosages ; Heart failure ; Hematology ; Kinases ; Medicine ; Medicine & Public Health ; mRNA ; Oncology ; Patients ; Prostate cancer ; Remission ; Remission (Medicine)</subject><ispartof>International journal of hematology, 2024-10, Vol.120 (4), p.512-514</ispartof><rights>Japanese Society of Hematology 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. Japanese Society of Hematology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c256t-d275abfca987e05613d6761e940f21e1934a6473fae6ae8cc31e526f6d02b353</cites><orcidid>0000-0003-0863-0739</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12185-024-03816-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12185-024-03816-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39023684$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yoshimaru, Ryo</creatorcontrib><creatorcontrib>Minami, Yosuke</creatorcontrib><title>Achievement of deep molecular response and treatment-free remission with asciminib treatment in CML</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><addtitle>Int J Hematol</addtitle><description>We evaluated the possibility of treatment-free remission (TFR) and durability of deep molecular response (DMR) with asciminib treatment by monitoring major BCR::ABL mRNA on the International Scale (BCR::ABL-IS) in 4 patients who needed to reduce or discontinue asciminib due to adverse event concerns, intolerance, or personal circumstances. IS increased in all 4 patients after discontinuation of asciminib, but 3 patients who resumed asciminib achieved DMR again. None of the patients achieved TFR with asciminib, but DMR could be achieved again by restarting asciminib after TFR failure. As this was a retrospective study in a small number of patients, no conclusions can be drawn regarding the possibility of TFR with asciminib. However, this study included patients with short treatment duration and DMR maintenance periods, so strict conditioning may be necessary. Safe dose reduction or TFR with asciminib may need to be considered in more cases.</description><subject>BCR-ABL protein</subject><subject>Case Report</subject><subject>Case reports</subject><subject>Drug dosages</subject><subject>Heart failure</subject><subject>Hematology</subject><subject>Kinases</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>mRNA</subject><subject>Oncology</subject><subject>Patients</subject><subject>Prostate cancer</subject><subject>Remission</subject><subject>Remission (Medicine)</subject><issn>0925-5710</issn><issn>1865-3774</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kUtvFDEQhC1ElCwhf4ADssSFi0m3PX7MMVqFh7SIS-6W19NDHM1jsWcg_HscNhCJA6c-9NfVpSrGXiG8QwB7WVCi0wJkI0A5NOL-GdugM1ooa5vnbAOt1EJbhDP2opQ7ALTQ2FN2plqQyrhmw-JVvE30nUaaFj73vCM68HEeKK5DyDxTOcxTIR6mji-ZwvIAij4T1d2YSknzxH-k5ZaHEtOYprR_4nia-Pbz7iU76cNQ6OJxnrOb99c3249i9-XDp-3VTkSpzSI6aXXY9zG0zhJog6oz1iC1DfQSCVvVBNNY1QcygVyMCklL05sO5F5pdc7eHmUPef62Ull89RdpGMJE81q8AicV1gigom_-Qe_mNU_VnFcIVqFzLVZKHqmY51Iy9f6Q0xjyT4_gHxrwxwZ8bcD_bsDf16PXj9LrfqTu78mfyCugjkCpq-kr5aff_5H9BdejkdE</recordid><startdate>20241001</startdate><enddate>20241001</enddate><creator>Yoshimaru, Ryo</creator><creator>Minami, Yosuke</creator><general>Springer Nature Singapore</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0863-0739</orcidid></search><sort><creationdate>20241001</creationdate><title>Achievement of deep molecular response and treatment-free remission with asciminib treatment in CML</title><author>Yoshimaru, Ryo ; Minami, Yosuke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c256t-d275abfca987e05613d6761e940f21e1934a6473fae6ae8cc31e526f6d02b353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>BCR-ABL protein</topic><topic>Case Report</topic><topic>Case reports</topic><topic>Drug dosages</topic><topic>Heart failure</topic><topic>Hematology</topic><topic>Kinases</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>mRNA</topic><topic>Oncology</topic><topic>Patients</topic><topic>Prostate cancer</topic><topic>Remission</topic><topic>Remission (Medicine)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoshimaru, Ryo</creatorcontrib><creatorcontrib>Minami, Yosuke</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoshimaru, Ryo</au><au>Minami, Yosuke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Achievement of deep molecular response and treatment-free remission with asciminib treatment in CML</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><addtitle>Int J Hematol</addtitle><date>2024-10-01</date><risdate>2024</risdate><volume>120</volume><issue>4</issue><spage>512</spage><epage>514</epage><pages>512-514</pages><issn>0925-5710</issn><issn>1865-3774</issn><eissn>1865-3774</eissn><abstract>We evaluated the possibility of treatment-free remission (TFR) and durability of deep molecular response (DMR) with asciminib treatment by monitoring major BCR::ABL mRNA on the International Scale (BCR::ABL-IS) in 4 patients who needed to reduce or discontinue asciminib due to adverse event concerns, intolerance, or personal circumstances. IS increased in all 4 patients after discontinuation of asciminib, but 3 patients who resumed asciminib achieved DMR again. None of the patients achieved TFR with asciminib, but DMR could be achieved again by restarting asciminib after TFR failure. As this was a retrospective study in a small number of patients, no conclusions can be drawn regarding the possibility of TFR with asciminib. However, this study included patients with short treatment duration and DMR maintenance periods, so strict conditioning may be necessary. Safe dose reduction or TFR with asciminib may need to be considered in more cases.</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><pmid>39023684</pmid><doi>10.1007/s12185-024-03816-x</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0003-0863-0739</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2024-10, Vol.120 (4), p.512-514 |
| issn | 0925-5710 1865-3774 1865-3774 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3082311700 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | BCR-ABL protein Case Report Case reports Drug dosages Heart failure Hematology Kinases Medicine Medicine & Public Health mRNA Oncology Patients Prostate cancer Remission Remission (Medicine) |
| title | Achievement of deep molecular response and treatment-free remission with asciminib treatment in CML |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T03%3A54%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Achievement%20of%20deep%20molecular%20response%20and%20treatment-free%20remission%20with%20asciminib%20treatment%20in%20CML&rft.jtitle=International%20journal%20of%20hematology&rft.au=Yoshimaru,%20Ryo&rft.date=2024-10-01&rft.volume=120&rft.issue=4&rft.spage=512&rft.epage=514&rft.pages=512-514&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-024-03816-x&rft_dat=%3Cproquest_cross%3E3082311700%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3107318891&rft_id=info:pmid/39023684&rfr_iscdi=true |